If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

31 Mar 2009 07:00

RNS Number : 7341P
GW Pharmaceuticals PLC
31 March 2009
Β 

ο»Ώ

31 March 2009

GW Pharmaceuticals plc

BLOCKLISTING INTERIMΒ REVIEW

1. NAME OF COMPANY:

GW PHARMACEUTICALS PLC

2. NAME OF SCHEME:

GW PHARMACEUTICALS APPROVED COMPANY SHARE OPTION SCHEME

3. PERIOD OF RETURN:

FROM: 25 JUNE 2008 TO: 31 MARCH 2009

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

145,400Β ORDINARY SHARES OF 0.1P EACH

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

NILΒ ORDINARY SHARES OF 0.1P EACH

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

145,400 ORDINARY SHARES OF 0.1P EACH

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

507,146 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

120,785,335 ORDINARY SHARES OF 0.1P EACH

BLOCKLISTING INTERIMΒ REVIEW

1. NAME OF COMPANY:

GW PHARMACEUTICALS PLC

2. NAME OF SCHEME:

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

3. PERIOD OF RETURN:

FROM: 25Β JUNE 2008 TO: 31 MARCH 2009

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

212,612 ORDINARY SHARES OF 0.1P EACH

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

NILΒ ORDINARY SHARES OF 0.1P EACH

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

212,612 ORDINARY SHARES OF 0.1P EACH

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYΒ LISTED AND THE DATE OF ADMISSION:

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERΒ FOR US TO UPDATE OUR RECORDS.

120,785,335 ORDINARY SHARES OF 0.1P EACH

BLOCKLISTING INTERIMΒ REVIEW

1. NAME OF COMPANY:

GW PHARMACEUTICALS PLC

2. NAME OF SCHEME:

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

3. PERIOD OF RETURN:

FROM: 25Β JUNE 2008 TO: 31 MARCHΒ 2009

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

423,758 ORDINARY SHARES OF 0.1P EACH

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

NIL ORDINARY SHARES OF 0.1P EACH

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

423,758 ORDINARY SHARES OF 0.1P EACH

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYΒ LISTED AND THE DATE OF ADMISSION:

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERΒ FOR US TO UPDATE OUR RECORDS.

120,785,335 ORDINARY SHARES OF 0.1P EACH

BLOCKLISTING INTERIMΒ REVIEW

1. NAME OF COMPANY:

GW PHARMACEUTICALS PLC

2. NAME OF SCHEME:

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

3. PERIOD OF RETURN:

FROM: 25Β JUNE 2008 TO: 31 MARCH 2009

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUEDΒ UNDER SCHEME AT END OF THE LAST PERIOD:

1,276,492 ORDINARY SHARES OF 0.1P EACH

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

NIL ORDINARY SHARES OF 0.1P EACH

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

1,276,492 ORDINARY SHARES OF 0.1P EACH

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLYΒ LISTED AND THE DATE OF ADMISSION:

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDERΒ FOR US TO UPDATE OUR RECORDS.

120,785,335 ORDINARY SHARES OF 0.1P EACH

For further information, please contact:

GW Pharmaceuticals plc

Adam George, Company Secretary +44 (0)Β 1980 557000

Nominated Adviser

Patrick Robb, Investec Bank plc +44 (0) 207 597 5970

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BLRZBLFXKXBEBBQ
Date   Source Headline
22nd Jun 20162:22 pmRNSHolding(s) in Company
21st Jun 201612:00 pmRNSEpidiolex Development Program in Infantile Spasms
17th Jun 20165:05 pmRNSHolding(s) in Company
8th Jun 20164:54 pmRNSHolding(s) in Company
31st May 20161:25 pmRNSTotal Voting Rights
31st May 201612:00 pmRNSPresents at Goldman Sachs and Jefferies Conference
16th May 201612:00 pmRNSGWP presenting at UBS Global Healthcare Conference
13th May 20163:50 pmRNSDirector/PDMR Shareholding
11th May 20165:19 pmRNSDirector/PDMR Shareholding
5th May 201612:00 pmRNSHalf-year Report
4th May 201612:00 pmRNSPresenting at BoAML 2016 Healthcare Conference
29th Apr 20161:37 pmRNSTotal Voting Rights
28th Apr 201612:00 pmRNSNotice of Results
21st Apr 201612:00 pmRNSOrphan Drug Designation for Cannabidiol in TSC
11th Apr 201612:00 pmRNSInitiates Ph 3 Study in Tuberous Sclerosis Complex
1st Apr 20163:24 pmRNSDirector/PDMR Shareholding
23rd Mar 20165:07 pmRNSResult of AGM
18th Mar 20163:34 pmRNSBlock Listing Application
14th Mar 201611:00 amRNSEpidiolex Positive Phase 3 Pivotal Study Results
29th Feb 20169:26 amRNSTotal Voting Rights
22nd Feb 20166:16 pmRNSNotice of AGM
17th Feb 201610:37 amRNSBlocklisting Interim Review
15th Feb 20162:39 pmRNSDirector/PDMR Shareholding
10th Feb 201612:00 pmRNS1st Quarter Results
4th Feb 20163:45 pmRNSPresenting at Leerink Global Healthcare Conference
2nd Feb 20163:07 pmRNSNotice of Results
29th Jan 201611:42 amRNSTotal Issued Share Capital
29th Jan 20169:29 amRNSHolding(s) in Company
28th Jan 20168:47 amRNSHolding(s) in Company
25th Jan 20168:33 amRNSHolding(s) in Company
6th Jan 201612:01 pmRNSPublication of UK Annual Report and Accounts
31st Dec 201510:42 amRNSTOTAL ISSUED SHARE CAPITAL
29th Dec 20152:26 pmRNSDirector/PDMR Shareholding
24th Dec 201512:00 pmRNSLancet Neurology Publishes Epidiolex Data
22nd Dec 20155:14 pmRNSDirector/PDMR Shareholding
21st Dec 20156:22 pmRNSDirector/PDMR Shareholding
16th Dec 20154:16 pmRNSDirector/PDMR Shareholding
16th Dec 20159:27 amRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSFinal Results
7th Dec 20156:00 pmRNSNew Physician Reports of Epidiolex Treatment
30th Nov 20151:00 pmRNSDate and Time Change for Q4 and FY 2015 Results
30th Nov 20159:38 amRNSTotal Voting Rights
25th Nov 20152:00 pmRNSEpidiolex data to be presented at AES Meeting
24th Nov 20156:00 pmRNSNotice of Results
24th Nov 20156:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
2nd Nov 201510:09 amRNSTotal Voting Rights
27th Oct 201511:05 amRNSAgreement with NSW to Study Epidiolex and CBDV
27th Oct 201511:00 amRNSResults from Sativex Phase 3 Cancer Pain Trials
15th Sep 20152:00 pmRNSPositive Proof of Concept Data in Schizophrenia
10th Sep 20152:00 pmRNSPresenting at Two Upcoming Investor Conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.